SNPMiner Trials (Home Page)
Report for Mutation M1106C
Developed by Shray Alag, 2020.
SNP Clinical Trial Gene
There is one clinical trial.
Clinical Trials
1 "Eye Protection After Mydriatic Use for ROP Screening: Impact on Vitals Signs and Pain Scores"
Pupillary dilation induced by mydriatic agents during Retinopathy of Prematurity exams can persist for hours. Despite regular use of eye protection for mydriatic-induced light sensitivity for infants, children and adults, eye protection after mydriasis has not been addressed in neonates. This study examines the use of eye patches to protect the dilated pupil from light exposure and their impact on vital signs and pain scores. prevents tachycardia, tachypnea and discomfort in neonates after ROP screening.
NCT01860534 Light Sensitivity Behavioral: eye covers MeSH:Photophobia
HPO:Photophobia
Heart rate was recorded directly from their cardio-respiratory monitor (Agilent M1106C). --- M1106C ---
Respiratory rate was recorded directly from their cardio-respiratory monitor (Agilent M1106C). --- M1106C ---
Oxygen percent saturation was recorded directly from their cardio-respiratory monitor (Agilent M1106C). --- M1106C ---
Primary Outcomes
Description: At 3 times (pre-mydriasis, 1 hour and 3 hours after Cyclomydril drops), subjects were exposed to ambient lighting for a period of five minutes. This usually entailed removing isolette covers and exposing the patient to the ambient room light. During this time, pain and vital signs were recorded every minute. Heart rate was recorded directly from their cardio-respiratory monitor (Agilent M1106C). The mean of the five recorded values for each variable was used
Measure: Heart Rate Time: pre-mydriasis, 1 hour and 3 hours after mydriatic dropsSecondary Outcomes
Description: At 3 times (pre-mydriasis, 1 hour and 3 hours after Cyclomydril drops), subjects were exposed to ambient lighting for a period of five minutes. This usually entailed removing isolette covers and exposing the patient to the ambient room light. During this time, pain and vital signs were recorded every minute. Respiratory rate was recorded directly from their cardio-respiratory monitor (Agilent M1106C). The mean of the five recorded values for each variable was used
Measure: Respiratory Rate Time: pre-mydriasis, 1 hour and 3 hours after mydriatic dropsDescription: At 3 times (pre-mydriasis, 1 hour and 3 hours after Cyclomydril drops), subjects were exposed to ambient lighting for a period of five minutes. This usually entailed removing isolette covers and exposing the patient to the ambient room light. During this time, pain and vital signs were recorded every minute. Oxygen percent saturation was recorded directly from their cardio-respiratory monitor (Agilent M1106C). The mean of the five recorded values for each variable was used
Measure: Oxygen Percent Saturation Time: pre-mydriasis, 1 hour and 3 hours after mydriatic dropsDescription: At 3 times (pre-mydriasis, 1 hour and 3 hours after Cyclomydril drops), subjects were exposed to ambient lighting for a period of five minutes. This usually entailed removing isolette covers and exposing the patient to the ambient room light. During this time, pain and vital signs were recorded every minute. Pain scores were recorded by direct observation using the Neonatal and Infant Pain Scale (NIPS). The mean of the five recorded values for each variable was used. NIPS scoring consists of 6 measures associated with neonatal or infant pain, each with a range of 0-7 with low scores (0-2) associated with no pain and scores > to 4 associated with severe pain. Maximum scoring would be 42 for severe pain and minimal being 0 for no pain. The six measures on NIPS include: facial expression, crying, breathing patterns, arm movements, leg movements and state of arousal.
Measure: Pain Time: pre-mydriasis, 1 hour and 3 hours after mydriatic drops